Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2007

View Archived Issues

KRAS mutation predicts response to panitumumab in colorectal cancer

Polyunsaturated fatty acid erythrocyte content, biomarker of colorectal cancer risk

Paliperidone ER improves sleep in patients with schizophrenia

AEGR-733 lowers LDL-cholesterol, body weight in hypercholesterolemic patients

Pooled DUET results show TMC-125 well tolerated in HIV-infected patients

Caspofungin effective in pediatric patients with fungal infections

Reduced levels of the mGlu3 receptor in the prefrontal cortex of schizophrenic patients

Anesiva reports on clinical plans for Adlea

Pharmion and MethylGene evaluate MGCD-0103 and Taxotere combination for solid tumors

C-Path and Ventana collaborate on targeted therapy initiative with FDA and NCI

Recent patents describe new antidiabetic agents

Positive phase II results reported for dry eye treatment ALTY-0501

Proteolix initiates carfilzomib study in relapsed solid tumors patients

Salvat completes enrollment in phase II SVT-40776 trial

NIH to sponsor preclinical DT-22669 diabetes study

Amarin initiates cardiovascular development strategy

Ark spins out eye-related discoveries to Eyecopharm

Drinkable typhoid vaccine candidate achieves phase II endpoints

Enrollment completed in phase I trial of Lenocta

Sontra Medical Corporation changes to Echo Therapeutics

FDA advisory committee recommends approval for Medtronic's drug-eluting stent

European health authorities accept marketing authorization application for alitretinoin

Novel treatment options for obesity and other metabolic disorders described in recent patents

Novel therapeutic agents for infectious diseases disclosed in recent patent literature

A farnesoid X receptor agonist for the treatment of dyslipidemia

FDA approves Isentress tablets for combination treatment of HIV-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...